Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella Sanofi en discussions pour céder une...
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants New...
Communiqué de presse : De nouvelles données sur le Beyfortus présentées à l’IDWeek confirment son efficacité en situation réelle contre les...
New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and...
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic...
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est le...
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent approved in the US as the...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on...
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU...
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO Dupixent, premier médicament...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD Dupixent approved in China as the first-ever...
Press Release: Availability of the Q3 2024 Aide mémoire Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi...
Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its...
Communiqué de presse : Mise en ligne du document «Q3 2024 Aide mémoire » Mise en ligne du document «Q3 2024 Aide mémoire » Paris, France, le 26...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관